PDCD1 and lymphoma: Even though MSI-associated hypermutation represents a potential biomarker for the efficacy of PD-1 blockade, it is likely infrequent in lymphoma; reported frequencies are low, occurring in only 0.46% of cHLs, 3.2% of DLBCLs and 8% of PMBCLs [160,161,172].